Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Director Purchases $2,399,232.93 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Director Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, May 5th. The shares were purchased at an average price of $24.63 per share, for a total transaction of $2,399,232.93. Following the completion of the purchase, the director directly owned 6,246,507 shares of the company’s stock, valued at $153,851,467.41. The trade was a 1.58% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Trading Down 2.4%

Shares of COAG opened at $25.12 on Friday. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.48 and a 12-month high of $36.61.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday.